Document:

<PAGE>

                                                                   EXHIBIT 10.21

                          SOMAXON PHARMACEUTICALS, INC.

                              CONSULTING AGREEMENT

      THIS CONSULTING AGREEMENT (this "AGREEMENT") is effective as of August 25,
2003 (the "EFFECTIVE DATE"), by and between SOMAXON PHARMACEUTICALS, INC., a
Delaware corporation (the "COMPANY"), and TERRY COBB (the "CONSULTANT").

Section 1. Services

      The Company hereby retains Consultant and Consultant hereby agrees to
render consulting services ("SERVICES") to the Company for the term of this
Agreement. The Services shall be those duties set forth in EXHIBIT A hereto,
which may be amended by the mutual consent of the parties. The Consultant will
not perform any Services for the Company except as authorized or requested by
the Company.

Section 2. TERM AND TERMINATION

      a.    This Agreement is effective as of the Effective Date, and will
            terminate on the date of acceptance for filing of an NDA for the
            initial Licensed Product (as each such term is defined in that
            certain License Agreement of even date herewith by and between the
            Company and ProCom One, Inc. (the "LICENSE AGREEMENT")) (the
            "TERMINATION DATE"), unless terminated earlier pursuant to
            subsection (b) below or extended by mutual consent of the Consultant
            and the Company.

      b.    This Agreement may be terminated by either the Company or the
            Consultant (a) for cause at any time prior to the Termination Date
            by giving written notice of termination setting forth in reasonable
            detail the basis for the termination and providing the other party
            with thirty (30) days' opportunity to cure or (b) upon the
            termination of the License Agreement.

      c.    Termination of this Agreement shall not affect (i) the Company's
            obligation to pay for Services previously rendered by the Consultant
            or expenses reasonably incurred by the Consultant for which the
            Consultant is entitled to reimbursement under Section 3 of this
            Agreement, or (ii) the Consultant's continuing obligations to the
            Company under Sections 5 and 6 of this Agreement.

      d.    In connection with the Consultant's Services to the Company, the
            Consultant agrees to be available for consultation by telephone, fax
            or e-mail on a regular basis throughout the year on reasonable prior
            notice, and be available to attend meetings with the Chairman, CEO
            or Board of Directors of the Company at the Company's headquarters
            on reasonable prior notice, in any case for not less than the
            equivalent of five (5) business days per month.

      e.    During the term of this Agreement, Consultant shall render the
            Services on an exclusive basis to the Company. However, it is
            understood by the Company that Consultant (i) is currently involved
            in ventures in other than the Consulting Field (as hereinafter
            defined), (ii) will involve himself in additional ventures in other
            than the Consulting Field during the term of this Agreement, and
            (iii) performs consulting services for third parties on matter
            outside of the Consulting Field. Company expressly agrees to
            Consultant's continued participation in such activities.
            Furthermore, Company expressly agrees to Consultant's participation
            in activities arising from opportunities that arise through the
            operation of Section 2(f) immediately below.

<PAGE>

      f     Consultant's Services as set forth in Exhibit A include the duty to
            "identify, cultivate and develop product licensing contacts,
            partnering contacts, corporate acquisition contacts and
            international business partners and to help the Company to negotiate
            related agreements within the Consulting Field" (each referred to as
            a "BUSINESS OPPORTUNITY"). In the event that the Company, after
            review and consideration of a given Business Opportunity, elects not
            to pursue such Business Opportunity, the Company shall promptly
            notify Consultant and Consultant shall be free to pursue such
            Business Opportunity independently of the Company and free of any
            financial or other obligations to the Company.

Section 3. COMPENSATION

      a.    As compensation for the Services to be rendered pursuant to this
            Agreement, the Company shall pay to Consultant the sum of $8,333 per
            month, to be paid monthly on the last calendar day of each month.
            Compensation for Consultant's services rendered during the first and
            last months shall be calculated on a pro-rata basis.

      b.    The Company shall reimburse, in accordance with its standard
            business practices, the Consultant's actual travel and other
            out-of-pocket expenses reasonably incurred in performing such
            Services after submission of reasonably detailed invoices
            documenting such expenses.

Section 4. RELATIONSHIP OF THE PARTIES; NO CONFLICTS

      a.    Notwithstanding any provision of this Agreement to the contrary, the
            Consultant is and shall at all times be an independent contractor
            and not an employee of the Company. The Consultant shall have no
            right under this Agreement, or as a result of his consulting
            services to the Company, to participate in any other employee,
            retirement, insurance or other benefit program of the Company, nor
            will the Company make any deductions from the Consultant's
            compensation for taxes, the payment of which shall be solely the
            Consultant's responsibility.

      b.    The Consultant shall pay, when and as due, any and all taxes
            incurred as a result of his compensation hereunder, including
            estimated taxes, and if requested by the Company, provide the
            Company with proof of said payments.

      c.    The Consultant represents and warrants that neither this Agreement
            nor the performance thereof will conflict with or violate any
            obligation of the Consultant or right of any third party.

Section 5. INTELLECTUAL PROPERTY

      a.    The Consultant agrees to assist the Company in any reasonable manner
            to obtain and enforce for the Company's benefit any patents,
            copyrights and other property rights in any and all countries, with
            respect to any Intellectual Property (defined below), and the
            Consultant agrees to execute, when requested, patent, copyright or
            similar applications and assignments to the Company and any other
            lawful documents deemed necessary by the Company to carry out the
            purposes of this Agreement with respect thereto. In the

                                       2
<PAGE>

            event that the Company is unable for any reason to secure, after
            making diligent efforts to do so, the Consultant's signature to any
            document required to apply for or execute any patent, copyright or
            other applications with respect to any Intellectual Property
            (including improvements, renewals, extensions, continuations,
            divisions or continuations in part thereof), after a written demand
            is made therefor upon the Consultant (which shall refer to the
            provisions of this paragraph), the Consultant hereby irrevocably
            designates and appoints the Company and its duly authorized officers
            and agents as the Consultant's agents and attorneys-in-fact to act
            for and on the Consultant's behalf and instead of the Consultant, to
            execute and file any such application and to do all other lawfully
            permitted acts to further the prosecution and issuance of patents,
            copyrights, mask works or other rights thereon with the same legal
            force and effect as if executed by the Consultant.

      b.    All right, title and interest of every kind and nature whatsoever in
            and to the Intellectual Property made, discussed, developed,
            secured, obtained or learned by the Consultant during the term of
            this Agreement shall be the sole and exclusive property of the
            Company for any purposes or uses whatsoever, and shall be disclosed
            promptly by the Consultant to the Company.

      c.    "INTELLECTUAL PROPERTY" includes any and all new or useful art,
            discovery, improvement, technical development, or invention, whether
            or not patentable and all related know-how, designs, trademarks,
            formulae, processes, manufacturing techniques, trade secrets, ideas,
            artworks, software or other copyrightable or patentable work, that
            the Consultant, solely or jointly with others, makes, conceives or
            reduces to practice which relate directly to the Consulting Field.

      d.    "CONSULTING FIELD" shall mean (i) the Field as defined in the
            License Agreement, and (ii) pharmaceuticals, the primary indication
            of which is in the field of psychiatry.

      e.    Improvements, as defined in the License Agreement, are subject to
            the right of reversion to ProCom One, Inc. as set forth in Section
            9.4 of the License Agreement. Somaxon acknowledges that Intellectual
            Property, as defined above, may include Improvements and that such
            inclusion shall not affect the operation of such Section 9.4.

Section 6. NONDISCLOSURE OF CONFIDENTIAL INFORMATION

      a.    The Consultant recognizes and acknowledges that certain knowledge
            and information which he or she may acquire or develop relating to
            the business of the Company, including, without limitation,
            technical and non-technical information including patent, copyright,
            trade secret, and proprietary information, techniques, sketches,
            drawings, models, inventions, know-how, processes, apparatus,
            equipment, algorithms, software programs, software source documents,
            and formulae related to the current, future and proposed products
            and services of the Company and its suppliers and customers, and
            includes, without limitation, its respective information concerning
            research, experimental work, development, design details and
            specifications, engineering, financial information, procurement
            requirements, purchasing, manufacturing, customer lists, business
            forecasts, sales and merchandising and marketing plans and
            information (collectively, "CONFIDENTIAL INFORMATION") are the
            valuable property of the Company or otherwise the subject of a
            license and/or right of first negotiation granted by ProCom One,
            Inc. to the Company pursuant to the License Agreement.

                                       3
<PAGE>

      b.    The Consultant covenants and agrees that, without the prior written
            consent of the Company, the Consultant will not use, disclose,
            divulge or publish any Confidential Information at any time during
            the term hereof or thereafter except as may be necessary to perform
            the Services; provided, however, that the Consultant shall not be
            obligated to treat as confidential, any Confidential Information
            that (i) was publicly known at the time of disclosure to the
            Consultant, (ii) becomes publicly known or available thereafter
            other than by means in violation of this Agreement or any other duty
            owed to the Company by the Consultant, or (iii) is lawfully
            disclosed to the Consultant by a third party.

      c.    The Consultant agrees not to disclose to the Company, or use in
            connection with the Consultant's efforts for the Company, any
            Confidential Information belonging to any third party, including the
            Consultant's prior employers, or any prior inventions made by him
            and which the Company is not otherwise legally entitled to learn of
            or use.

      d.    Upon termination of his service hereunder, the Consultant agrees to
            promptly deliver to the Company, all Confidential Information
            belonging to the Company in his possession that is written or other
            tangible form (together with all copies or duplicates thereof,
            including computer files), and all other property, materials or
            equipment that belong to the Company, its customers or its
            suppliers.

Section 7. NON-SOLICITATION

      a.    During the term of this Agreement and for a period of twelve (12)
            months thereafter, the Consultant agrees that, without the prior
            written consent of the Company, the Consultant will not, directly or
            indirectly, on his behalf or on behalf of any other person or
            entity, (i) call upon, solicit, divert or take away or attempt to
            solicit, divert or take away any of the customers, business or
            consultants of the Company; or (ii) employ, solicit or attempt to
            solicit for employment any person who is then an employee of the
            Company or who was an employee of the Company at any time during the
            twelve (12) month period immediately prior to the date of the
            subject solicitation.

      b.    The parties acknowledge that the foregoing restrictions placed upon
            the Consultant are necessary and reasonable in scope and duration
            and are a material inducement to the Company to execute, deliver and
            perform its obligations arising under or pursuant to this Agreement,
            and that despite such restrictions the Consultant will be able to
            earn his livelihood and engage in his profession during the term of
            this Agreement.

Section 8. INDEMNIFICATION

      a.    The Company shall indemnify, defend and hold harmless the Consultant
            from and against losses and expenses (including reasonable
            attorneys' fees, judgments, settlements and all other costs, direct
            or indirect) actually and reasonably incurred by reason of, or based
            upon, any threatened, pending or completed action, suit, proceeding,
            investigation or other dispute relating or pertaining to any alleged
            act or failure to act within the scope of the Services, provided
            that the Consultant acted in good faith and in a manner the
            Consultant reasonably believed to be in the best interests of the
            Company and, if any criminal proceedings are involved, had no
            reasonable cause to believe the Consultant's conduct was unlawful.

                                       4
<PAGE>

      b.    The Consultant agrees to cooperate in all respects with the Company
            in the defense of any such claim. The Consultant also agrees and
            undertakes to repay defense costs and expenses, including attorneys'
            fees, reasonably incurred in defending against any such claim which
            may be advanced by the Company prior to the final disposition of any
            proceeding relating to such claim, if a court of competent
            jurisdiction ultimately shall determine that the Consultant is not
            entitled to indemnification pursuant to this Agreement or the
            indemnification is not consistent with any applicable law or
            regulation.

Section 9. RIGHTS AND REMEDIES UPON BREACH

            If the Consultant breaches or threatens to commit a breach of any of
            the provisions of Sections 5, 6 or 7 of this Agreement (the
            "RESTRICTIVE COVENANTS"), the Company shall have the right and
            remedy to seek specific enforcement of the Restrictive Covenants by
            any court of competent jurisdiction, it being agreed that any breach
            or threatened breach of the Restrictive Covenants may cause
            irreparable injury to the Company and that money damages may not
            provide an adequate remedy to the Company. The Company shall also
            have any other rights and remedies available to the Company under
            law or in equity.

Section 10. MISCELLANEOUS

      a.    This Agreement shall be governed in all respects by the laws of the
            State of California, without regard to any provisions thereof
            relating to conflict of laws among different jurisdictions.

      b.    Except as provided in Section 9 above, the parties agree that any
            dispute or controversy arising out of or relating to any
            interpretation, construction, performance or breach of this
            Agreement shall be settled by arbitration to be held in San Diego
            County, California, in accordance with the rules then in effect of
            the American Arbitration Association. The arbitrator may grant
            injunctions or other relief in such dispute or controversy, and may
            award the prevailing party its counsel fees and expenses. The
            decision of the arbitrator shall be final, conclusive and binding on
            the parties to the arbitration. Judgment may be entered on the
            arbitrator's decision in any court of competent jurisdiction. The
            costs and expenses of such arbitration, including each party's
            respective counsel fees and expenses, shall be paid by the
            non-prevailing party, unless otherwise determined by the arbitrator.

      c.    This Agreement, together with the License Agreement, set forth the
            entire agreement of the parties with respect to the Services to be
            provided by the Consultant and supersedes any prior agreements or
            term sheets between them with respect to the subject matter of this
            Agreement. This Agreement may only be amended in writing by the
            Company and the Consultant and their respective permitted successors
            and assigns.

      d.    Neither party may subcontract or otherwise delegate its obligations
            under this Agreement without the other party's prior written
            consent, and the services to be provided by the Consultant hereunder
            may only be performed by the Consultant personally. Subject to the
            foregoing, this Agreement will be binding upon and inure to the
            benefit of the parties and their respective heirs, legal
            representatives, successors and assigns.

      e.    Either party's failure to enforce any right resulting from a breach
            of any provision of this Agreement shall not operate or be construed
            as a waiver of any other or subsequent breach by the other party.

                                       5
<PAGE>

      f.    All notices required or permitted to be given by one party to the
            other under this Agreement shall be sufficient if sent by either
            certified mail return receipt requested, nationally recognized
            courier, facsimile or hand delivery to the parties at the respective
            addresses set forth below or to such other address as the party to
            receive the notice has designated by written notice to the other
            party. All notices shall be effective (i) when delivered personally,
            (ii) when transmitted by telecopy, electronic or digital
            transmission with receipt confirmed, (iii) the business day when
            delivered by a nationally recognized courier, or (iv) upon receipt
            if sent by certified or registered mail.

      g.    If any of the provisions of this Agreement are found to be invalid
            under an applicable statute or rule of law, they are to be enforced
            to the maximum extent permitted by law and beyond such extent are to
            be deemed omitted from this Agreement, without affecting the
            validity of any other provision of this Agreement.

      h.    This Agreement may be executed in counterparts, each of which will
            be deemed an original and all of which together shall constitute one
            and the same instrument.

                  [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       6
<PAGE>

      Having understood and agreed to the foregoing, the Company and the
Consultant have signed this Agreement as of the day and year written above.

CONSULTANT                              SOMAXON PHARMACEUTICALS, INC.

/s/ Terry Cobb                          By: /s/ Kenneth Cohen
----------------------                      ------------------------
Name: Terry Cobb                            Name: Kenneth Cohen
                                            Title: President and Chief Executive
                                                   Officer

<PAGE>

                                    EXHIBIT A

                              DUTIES OF CONSULTANT

Consultant shall perform the following duties for the Company:

      -     Provide strategic advice and review concerning the Company's product
            development efforts, including research and clinical development
            programs within the Consulting Field;

      -     Identify, cultivate and develop product licensing contacts,
            partnering contacts, corporate acquisition contacts and
            international business partners and negotiate related agreements
            within the Consulting Field; and

      -     Provide such other assistance within the Consulting Field as may be
            reasonably requested by the Company.

"CONSULTING FIELD" shall mean (i) the Field as defined in the License Agreement,
and (ii) pharmaceuticals, the primary indication of which is in the field of
psychiatry.<PAGE>

                                                                   EXHIBIT 10.22

                          SOMAXON PHARMACEUTICALS, INC.

                         COMMON STOCK PURCHASE AGREEMENT

      THIS COMMON STOCK PURCHASE AGREEMENT ("AGREEMENT") is made as of April 15,
2004 by and among Somaxon Pharmaceuticals, Inc., a Delaware corporation (the
"COMPANY"), ProCom One, Inc. ("PROCOM") and Terry Cobb, an individual (the
"PURCHASER").

      The parties agree as follows:

      1.    Issuance of Stock. In partial consideration for the license grant
and other covenants of ProCom under that certain License Agreement dated August
25, 2003 by and between the Company and ProCom (the "LICENSE AGREEMENT"), the
Company hereby agrees to issue to the Purchaser, as the designee of ProCom under
Section 4.7 of the License Agreement, and the Purchaser hereby accepts, an
aggregate of 201,739 shares of the Company's Common Stock (par value $0.0001 per
share) (the "SHARES").

      2.    Capitalization as of the Qualified Financing. The Company
represents and warrants to the Purchaser that, as of the effective date of the
Qualified Financing (as defined in the License Agreement), the outstanding
capital stock of the Company consisted of 2,300,000 shares of Series A Preferred
Stock and 3,500,000 shares of Common Stock. Accordingly, the Shares issued to
the Purchaser hereunder, together with the shares of Common Stock to be issued
concurrently to the other designee of ProCom under Section 4.7 of the License
Agreement, Dr. Neil B. Kavey, constitute eight percent (8.0%) of the outstanding
capital stock of the Company as of the Qualified Financing.

      3.    Right of First Refusal. The Purchaser shall be entitled to become
a party to the Company's Amended and Restated Investor Rights Agreement, dated
as of December 15, 2003 (the "RIGHTS AGREEMENT"), solely for the purpose of the
right of first refusal set forth in Section 4 thereof. Upon the Purchaser's
execution and delivery to the Company of a counterpart signature page to the
Rights Agreement, the Purchaser shall be deemed to be an "Investor" for purposes
of Section 4 of the Rights Agreement and the provisions of Section 4.7.3 of the
License Agreement shall be deemed satisfied in their entirety.

      4.    Investment Representations. In connection with the purchase of
the Shares, the Purchaser represents to the Company the following:

            (a)   The Shares to be issued to the Purchaser hereunder will be
acquired for investment for the Purchaser's own account and not with a view to
the public resale or distribution thereof within the meaning of the Securities
Act of 1933, as amended (the "SECURITIES ACT").

            (b)   The Purchaser has received or has had full access to all
the information the Purchaser considers necessary or appropriate to make an
informed investment decision with respect to the Shares.

            (c)   The Purchaser understands that an investment in the Shares
involves substantial risk. The Purchaser: (i) has experience as an investor in
securities of companies in the development stage and acknowledges that the
Purchaser is able to fend for itself, can bear the economic risk of the
Purchaser's investment in the Shares and has such knowledge and experience in
financial or business matters that it is capable of evaluating the merits and
risks of its investment in the Shares and protecting its investment; and/or (ii)
has a preexisting business relationship with the Company and/or certain of its
other officers, directors or controlling persons of a nature and duration that
enables the Purchaser to be aware of the character, business acumen and
financial circumstances of such persons.

<PAGE>

            (d)   Purchaser is an accredited investor within the meaning of
Regulation D promulgated under the Securities Act.

            (e)   The Purchaser understands that the Shares are
characterized as "restricted securities" under the Securities Act, in a
transaction not involving a public offering and that under the Securities Act
and applicable regulations thereunder such securities may be resold without
registration under the Securities Act only in certain limited circumstances. The
Purchaser represents that it is familiar with Rule 144 of the Securities and
Exchange Commission and understands the resale limitations imposed thereby and
by the Securities Act. The Purchaser understands that the Company is under no
obligation to register any of the securities sold hereunder.

      5.    Stock Certificate Legends. The share certificate evidencing the
Shares issued hereunder shall be endorsed with the following legends:

            (a)   THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN
REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE "ACT"), AND HAVE
BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE
SALE OR DISTRIBUTION THEREOF. NO SUCH SALE OR DISTRIBUTION MAY BE EFFECTED
WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF
COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT
REQUIRED UNDER THE ACT OR UNLESS SOLD PURSUANT TO RULE 144 OF SUCH ACT.

            (b)   Any legend required by the Company's Bylaws and any
applicable state securities laws.

      6.    Market Stand-Off Agreement. The Purchaser hereby agrees, if so
requested by the managing underwriters or the Company in connection with the
initial public offering of the Company's Common Stock, that, without the prior
written consent of such managing underwriters, the Purchaser will not offer,
sell, contract to sell, grant any option to purchase, make any short sale or
otherwise dispose of, assign any legal or beneficial interest in or make a
distribution of any capital stock of the Company held by or on behalf of the
Purchaser or beneficially owned by the Purchaser in accordance with the rules
and regulations of the Securities and Exchange Commission for a period of up to
180 days after the date of the final prospectus relating to the Company's
initial public offering.

      7.    California Corporate Securities Law. THE SALE OF THE SECURITIES
WHICH ARE THE SUBJECT OF THIS AGREEMENT HAS NOT BEEN QUALIFIED WITH THE
COMMISSIONER OF CORPORATIONS OF THE STATE OF CALIFORNIA AND THE ISSUANCE OF SUCH
SECURITIES OR THE PAYMENT OR RECEIPT OF ANY PART OF THE CONSIDERATION THEREFOR
PRIOR TO SUCH QUALIFICATION IS UNLAWFUL, UNLESS THE SALE OF SECURITIES IS EXEMPT
FROM THE QUALIFICATION BY SECTION 25100, 25102, OR 25105 OF THE CALIFORNIA
CORPORATIONS CODE. THE RIGHTS OF ALL PARTIES TO THIS AGREEMENT ARE EXPRESSLY
CONDITIONED UPON SUCH QUALIFICATION BEING OBTAINED, UNLESS THE SALE IS SO
EXEMPT.

      8.    General Provisions.

            (a)   This Agreement shall be governed by the laws of the State
of California. This Agreement represents the entire agreement between the
parties with respect to the purchase of Common Stock by the Purchaser and may
only be modified or amended in writing signed by both parties.

            (b)   Any notice, demand or request required or permitted to be
given by either the Company or the Purchaser pursuant to the terms of this
Agreement shall be in writing and shall

<PAGE>

be deemed given when delivered personally or deposited in the U.S. mail, First
Class with postage prepaid, and addressed to the parties at the addresses of the
parties set forth at the end of this Agreement or such other address as a party
may request by notifying the other in writing.

            (c)   The rights and benefits of the Company under this
Agreement shall be transferable to any one or more persons or entities, and all
covenants and agreements hereunder shall inure to the benefit of, and be
enforceable by the Company's successors and assigns. The rights and obligations
of the Purchaser under this Agreement may only be assigned with the prior
written consent of the Company and any purported transfer otherwise shall be
null and void.

            (d)   Either party's failure to enforce any provision or
provisions of this Agreement shall not in any way be construed as a waiver of
any such provision or provisions, nor prevent that party thereafter from
enforcing each and every other provision of this Agreement. The rights granted
both parties herein are cumulative and shall not constitute a waiver of either
party's right to assert all other legal remedies available to it under the
circumstances.

            (e)   Purchaser acknowledges that the Shares are subject to a
right of first refusal pursuant to the Company's Bylaws, a copy of which is
available from the Secretary of the Company.

            (f)   The Purchaser agrees upon request to execute any further
documents or instruments necessary or desirable to carry out the purposes or
intent of this Agreement.

            (g)   Purchaser has reviewed this Agreement in its entirety, has
had an opportunity to obtain the advice of counsel prior to executing this
Agreement and fully understands all provisions of this Agreement.

                  [Remainder of page intentionally left blank]

<PAGE>

      IN WITNESS WHEREOF, the parties have duly executed this Agreement as of
the date first set forth above.

COMPANY:                                        PURCHASER:

SOMAXON PHARMACEUTICALS, INC.,
a Delaware corporation                          /s/ Terry Cobb
                                                --------------------------------
                                                Terry Cobb

By: /s/ Kenneth Cohen                           Address:  c/o Key Concepts
    ------------------------------------                  13880 Perdido Key
    Name:  Kenneth Cohen                                  Florida 32507
    Title: President and Chief Executive
           Officer

Address:  12750 High Bluff Drive, Suite 310
          San Diego, California 92130

Acknowledged and Agreed:

PROCOM ONE, INC.

By: /s/ Neil Kavey
    ------------------------------------
    Name:  Neil B. Kavey, M.D.
    Title:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00091-of-00352.parquet"}]]